Theriva Biologics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Theriva Biologics, Inc. (TOVX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.65% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-11
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 3.65%.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-06-30 was 2.65%.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2019-03-31 was 2.75%.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2015-09-30 was 0.00%.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 3.74%, a 3.61% decline from fiscal 2024.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 3.88%, a 3.48% decline from fiscal 2023.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.02%.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2021 was 1.12%, a 261.29% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 3.65% 10-Q · filed 2026-08-11 | ||||
| 2026-03-31 | 3.65% 10-Q · filed 2026-05-05 | ||||
| 2025-12-31 | 3.74% 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | 3.74% 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | 3.74% 10-Q · filed 2026-08-11 | ||||
| 2024-12-31 | 3.88% 10-K · filed 2026-03-12 | ||||
| 2023-12-31 | 4.02% 10-K · filed 2025-03-06 | ||||
| 2022-09-30 | 2.65% 10-Q · filed 2022-11-10 | ||||
| 2022-06-30 | 2.65% 10-Q · filed 2022-08-11 | 2.65% 10-Q · filed 2022-08-11 | |||
| 2021-12-31 | 1.12% 10-K · filed 2023-03-30 | ||||
| 2020-12-31 | 0.31% 10-K · filed 2022-03-16 | ||||
| 2019-12-31 | 1.61% 10-K · filed 2021-03-04 | ||||
| 2019-06-30 | 2.75% 10-Q · filed 2019-08-08 | ||||
| 2019-03-31 | 2.75% 10-Q · filed 2019-05-08 | ||||
| 2018-12-31 | 2.75% 10-K · filed 2020-02-20 | ||||
| 2015-09-30 | 0.00% 10-Q · filed 2015-11-05 | ||||
| 2015-03-31 | 2.03% 10-Q · filed 2016-05-05 | ||||
| 2014-03-31 | 1.57% 10-Q · filed 2015-05-11 | ||||
| 2013-12-31 | 0.26% 10-K · filed 2015-03-16 | ||||
| 2013-09-30 | 0.00% 10-Q · filed 2014-11-14 | 0.77% 10-Q · filed 2014-11-14 | |||
| 2013-06-30 | 0.00% 10-Q · filed 2014-08-14 | 0.77% 10-Q · filed 2014-08-14 | |||
| 2013-03-31 | 0.77% 10-Q · filed 2014-05-15 | ||||
| 2012-12-31 | 0.71% 10-K · filed 2015-03-16 | 0.26% 10-K · filed 2013-04-16 | |||
| 2011-12-31 | 0.71% 10-K · filed 2013-04-16 | ||||
| 2011-06-30 | 2.88% 10-Q/A · filed 2012-09-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |